DarioHealth Corp. (DRIO)
After hours:
| Previous close | 1.6600 |
| Open | 1.6500 |
| Bid | 1.5200 x 100 |
| Ask | 1.6100 x 100 |
| Day's range | 1.5500 - 1.6500 |
| 52-week range | 0.6800 - 4.5800 |
| Volume | |
| Avg. volume | 123,541 |
| Market cap | 46.577M |
| Beta (5Y monthly) | 1.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9300 |
| Earnings date | 15 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.67 |
PR NewswireDarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time.
- PR Newswire
Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR) demonstrating a clinically significant reduction in blood glucose levels for members using Dario to manage weight alongside diabetes.
- PR Newswire
Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two employers beginning in the second quarter of 2024.
